Two different molecules, both injected weekly, both approved for type 2 diabetes. The data says tirzepatide wins on every clinical endpoint. Here is exactly how much, and when it matters.
🔑 Key Takeaways
- Mounjaro (tirzepatide, Eli Lilly) and Ozempic (semaglutide, Novo Nordisk) are both weekly injectable GLP-1 receptor agonists approved for type 2 diabetes. Neither is approved for weight loss (the weight-loss brands are Zepbound and Wegovy respectively)
- Mounjaro is a dual agonist that activates both GLP-1 and GIP receptors. Ozempic is a single GLP-1 agonist. This is the core biological difference
- In the SURPASS-2 head-to-head trial, Mounjaro 15 mg produced an average HbA1c reduction of about 2.3% and ~12 kg weight loss, compared to Ozempic 1.0 mg at about 1.9% HbA1c and ~6 kg weight loss
- Ozempic has two unique approvals Mounjaro does not: cardiovascular risk reduction in T2D patients with established CV disease, and kidney disease protection in T2D with chronic kidney disease
- Both require once-weekly subcutaneous injection. Dose escalation is slow for both to reduce GI side effects
- Side effect profiles are similar (both are GLP-1-based) with slightly higher rates on Mounjaro because GIP adds its own signaling layer
- Cost is comparable: Mounjaro ~$1,020/month list price, Ozempic ~$900/month. Both have commercial insurance coverage for T2D with standard prior authorization
- Off-label use for weight loss is common with both. For FDA-approved weight management, Zepbound (tirzepatide) and Wegovy (semaglutide) are the on-label choices
This page is the full Mounjaro vs Ozempic comparison: mechanisms, FDA indications, SURPASS vs SUSTAIN trial data, weight loss, HbA1c reduction, side effects, cost, insurance, cardiovascular and kidney outcome data, and who should pick which.
What's the Difference Between Mounjaro and Ozempic?
Two different molecules. One hits one receptor. The other hits two.
Ozempic contains semaglutide, a GLP-1 receptor agonist engineered for weekly dosing. Mounjaro contains tirzepatide, a dual agonist that activates both the GLP-1 receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor. Adding GIP produces stronger HbA1c reduction and more weight loss compared to activating GLP-1 alone. Tirzepatide consistently outperforms semaglutide in head-to-head trials for both glycemic control and weight loss.
Mounjaro vs Ozempic: Specs Side-by-Side
| Mounjaro | Ozempic | |
|---|---|---|
| Active ingredient | Tirzepatide | Semaglutide |
| Manufacturer | Eli Lilly | Novo Nordisk |
| Receptors | GLP-1 + GIP (dual) | GLP-1 only |
| FDA indication | Type 2 diabetes | T2D, CV risk reduction in T2D, kidney protection in T2D |
| FDA approval year | May 2022 | December 2017 |
| Dose range | 2.5 to 15 mg weekly | 0.25 to 2.0 mg weekly |
| Injection frequency | Once weekly | Once weekly |
| HbA1c reduction (max dose) | ~2.3% (SURPASS-2) | ~1.9% (SURPASS-2 comparator) |
| Weight loss in T2D (max dose) | ~12 kg (SURPASS-2) | ~6 kg (SURPASS-2 comparator) |
| List price / month | ~$1,020 | ~$900 |
| Weight-loss brand equivalent | Zepbound | Wegovy |
How They Work: The GLP-1 + GIP Difference
GLP-1 and GIP are the two main incretin hormones. After a meal, the gut releases both. Each triggers pancreatic insulin secretion, each affects appetite, and each influences fat metabolism.
Ozempic (semaglutide) is engineered to activate only the GLP-1 receptor. It does this very effectively, which is why it produces 14 to 15% weight loss at the Wegovy dose and strong HbA1c reduction at the Ozempic dose.
Mounjaro (tirzepatide) activates both the GLP-1 receptor and the GIP receptor. The discovery that surprised researchers around 2012 was that combining both in one molecule produced synergistic effects, even though earlier GIP-alone research had suggested GIP might promote obesity. In combination with GLP-1 activity, GIP receptor activation actually enhances weight loss and glycemic control.
This dual mechanism is the biological reason tirzepatide outperforms semaglutide in every head-to-head trial completed so far.
FDA-Approved Uses: Where Ozempic Has More
Mounjaro approvals
- Type 2 diabetes: Adjunct to diet and exercise to improve glycemic control in adults with T2D
- Can be combined with: Metformin, sulfonylureas, insulin, thiazolidinediones
- Not approved for: Weight loss (Zepbound is the weight-loss brand of tirzepatide), CV risk reduction, kidney disease
Ozempic approvals
- Type 2 diabetes: Same primary indication as Mounjaro
- Cardiovascular risk reduction: Adults with T2D and established cardiovascular disease, based on the SUSTAIN-6 trial
- Kidney disease protection: Adults with T2D and chronic kidney disease (Ozempic-specific indication as of 2025)
Ozempic has two CV and kidney outcome indications Mounjaro does not have yet. This matters specifically for patients with T2D plus established cardiovascular disease or CKD. The SURPASS-CVOT trial for tirzepatide is ongoing and may add these indications in the future, but the current labeling gives Ozempic the edge for those populations.
Head-to-Head: The SURPASS-2 Trial
The direct comparison that settled the question.
SURPASS-2 randomized 1,879 adults with type 2 diabetes on metformin to tirzepatide (5, 10, or 15 mg weekly) or semaglutide 1.0 mg weekly for 40 weeks. The results, published in NEJM 2021:
| Tirzepatide 5 mg | Tirzepatide 10 mg | Tirzepatide 15 mg | Semaglutide 1.0 mg | |
|---|---|---|---|---|
| HbA1c reduction | -2.01% | -2.24% | -2.30% | -1.86% |
| Weight loss | -7.6 kg | -9.3 kg | -11.2 kg | -5.7 kg |
| % achieving HbA1c <7% | 82% | 86% | 86% | 79% |
Every dose of tirzepatide outperformed semaglutide 1.0 mg on both endpoints. The 15 mg dose produced roughly 2x the weight loss. The trial had a 2.0 mg semaglutide arm added later, which narrowed the gap slightly, but tirzepatide 15 mg still beat semaglutide 2.0 mg on both HbA1c and weight loss.
Dosing and Titration
Mounjaro Titration
- Weeks 1-4: 2.5 mg once weekly (priming dose, not expected to hit full glycemic effect)
- Weeks 5-8: 5 mg once weekly (first therapeutic dose)
- Increase by 2.5 mg every 4 weeks as needed: 7.5 → 10 → 12.5 → 15 mg
- Target maintenance: 5, 10, or 15 mg depending on glycemic response and tolerance
Ozempic Titration
- Weeks 1-4: 0.25 mg once weekly (starting, not yet therapeutic)
- Weeks 5-8: 0.5 mg once weekly (first therapeutic dose)
- Increase after at least 4 weeks as needed: 1.0 mg → 2.0 mg max
- Target maintenance: 0.5, 1.0, or 2.0 mg
Both drugs titrate slowly to reduce nausea and vomiting. Holding a dose level for an extra 4 weeks when side effects are strong is a valid strategy with both. There is no prize for moving up the schedule quickly.
Mounjaro vs Ozempic Side Effects
Similar profiles, slightly higher rates on Mounjaro at max dose.
| Side effect | Mounjaro 15 mg | Ozempic 1.0 mg |
|---|---|---|
| Nausea | ~29% | ~20% |
| Diarrhea | ~23% | ~12% |
| Vomiting | ~10% | ~9% |
| Constipation | ~17% | ~5% |
| Decreased appetite | ~11% | ~8% |
| Injection site reactions | Variable | Variable |
Both carry the identical class boxed warning for medullary thyroid carcinoma and MEN2 family history. Both carry the same rare risks: pancreatitis (0.1 to 0.2% incidence), gallbladder disease, kidney injury from severe dehydration, hypersensitivity reactions, and possible diabetic retinopathy worsening in patients with pre-existing retinopathy.
See our tirzepatide side effects guide and Ozempic side effects pages for complete profiles.
Cost and Insurance Comparison
| Option | Mounjaro | Ozempic |
|---|---|---|
| List price (cash) | ~$1,020/month | ~$900/month |
| Manufacturer savings card | Lilly Mounjaro Savings Card (commercial insurance required) | Novo Nordisk savings (commercial insurance required) |
| Commercial insurance (T2D) | $25-$250 copay with PA | $25-$200 copay with PA |
| Medicare Part D | Covered for T2D | Covered for T2D |
| Medicaid | Varies by state, usually covered for T2D | Varies by state, usually covered for T2D |
| Cash for off-label weight use | List price (no cash discount) | List price (no cash discount) |
For T2D patients, insurance usually covers both drugs with standard prior authorization. Off-label weight loss use is a different story: insurance typically denies both Mounjaro and Ozempic prescriptions when there is no T2D diagnosis. Patients who want weight loss should switch to the on-label brand (Zepbound for tirzepatide, Wegovy for semaglutide) where manufacturer cash programs and weight-specific PAs apply.
Cardiovascular and Kidney Outcomes
This is where Ozempic has a clinical edge Mounjaro has not yet earned.
- SUSTAIN-6 (Ozempic, NEJM 2016): 26% reduction in major adverse cardiovascular events (MACE) in T2D patients with established CV disease. This trial established Ozempic's CV indication
- FLOW (Ozempic, 2024): Demonstrated kidney protection in T2D patients with chronic kidney disease. Led to the kidney disease indication added in 2025
- SURPASS-CVOT (Mounjaro): Ongoing cardiovascular outcomes trial. Results pending. Until published and submitted to FDA, Mounjaro does not carry a CV indication despite documented benefits in shorter trials
For T2D patients with established cardiovascular disease or CKD, Ozempic has proven outcomes data Mounjaro does not have yet. The tradeoff is worth noting when deciding between the two for these specific populations.
Who Should Pick Mounjaro vs Ozempic
Pick Mounjaro if
- You have type 2 diabetes and want maximum HbA1c reduction
- Glycemic control is not adequate on metformin alone, or on a GLP-1 mono-agonist, and you want the dual agonist mechanism
- Weight loss is a strong secondary goal alongside T2D management
- You have obstructive sleep apnea with obesity (switch to Zepbound, the weight brand of tirzepatide)
- You want the most effective injectable diabetes drug on the market
Pick Ozempic if
- You have type 2 diabetes plus established cardiovascular disease (Ozempic's unique CV indication)
- You have type 2 diabetes plus chronic kidney disease (Ozempic's kidney protection indication)
- Insurance denies Mounjaro but approves Ozempic
- You prefer multi-dose pens over single-dose injection devices
- You want proven cardiovascular outcomes data alongside glycemic control
For the broader context including weight-loss-specific comparisons, see our weight loss drugs reference or the full GLP-1 peptides comparison.
Can You Switch from Ozempic to Mounjaro?
Yes, and it is common. Because they are different molecules, the switch requires restarting titration at the new drug's lowest dose regardless of where you were on the old drug. If you were on Ozempic 1.0 mg weekly, you would start Mounjaro at 2.5 mg weekly and titrate up from there.
Allow at least 1 week between the last Ozempic dose and the first Mounjaro dose. Patients commonly switch from Ozempic to Mounjaro when glycemic control is inadequate on semaglutide alone, or when they want to try the dual agonist for additional weight loss. Switching in the other direction (Mounjaro to Ozempic) is less common but done when patients need the CV or kidney outcome data Ozempic carries.